Rituximab in rheumatoid arthritis following anti-TNF-associated tuberculosis

Rheumatology

Volumn 47, Issue 5, 2008, Pages 738-739

  Burr, M L ^a   Malaviya, A P ^a   Gaston, J H ^a   Carmichael, A J ^a   Ostor A J K ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; ETHAMBUTOL; INFLIXIMAB; ISONIAZID; METHOTREXATE; METHYLPREDNISOLONE; MOXIFLOXACIN; PREDNISOLONE; PYRAZINAMIDE; RIFAMPICIN; RITUXIMAB; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ANTIBODY;

ACID FAST BACTERIUM; ADULT; ANTIBIOTIC RESISTANCE; ARTHRALGIA; BACTERIAL STRAIN; BRONCHOSCOPY; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FEVER; GRANULOMATOSIS; HUMAN; LETHARGY; LETTER; LIVER INJURY; LUNG LAVAGE; LUNG NODULE; LUNG TUBERCULOSIS; MAINTENANCE THERAPY; MYCOBACTERIUM TUBERCULOSIS; NIGHT SWEAT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RELAPSE; REMISSION; RHEUMATOID ARTHRITIS; SCORING SYSTEM; TRANSBRONCHIAL BIOPSY;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ANTITUBERCULAR AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 42949104981     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken113     Document Type: Letter

References (8)

1. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumour necrosis factor alpha-neutralising agent. N Engl J Med 2001;345:1098-104.
2. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumour necrosis factor antagonists. Clin Infect Dis 2004;38:1261-5.
3. Gomez-Reino JJ, Carmona L, Valverde VR at al. BIOBADASER group. Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multi-centre active surveillance report. Arthritis Rheum 2003;48:2122-7.
4. Cohen SB, Emery P, Greenwald MW et al. for the REFLEX trial group. Rituximab for rheumatoid arthritis refractory to anti-tumour necrosis factor therapy. Arthritis Rheum 2006;54:2793-806.
5. Emery P, Fleischmann R, Filipowicz-Sosnowska A et al. for the DANCER study group. The efficacy and safety of rituximab in patients With active rheumatoid arthritis despite methotrexate treatment. Results of a phase IIb randomised, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400.
6. Smolen JS, Keystone EC, Emery P at al. The Working Group on the Rituximab Consensus Statement. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:143-50.
7. Mohrbacher A. B cell non-Hodgkin's lymphoma: Rituximab safety experience. Arthritis Res Ther 2005;7(Suppl 3):S19-25.
8. Lehembre S, Macario-Barrel A, Musette P, Carvalho P, Joly P. Rituximab treatment for immune thrombocytopenia associated with systemic lupus erythematosus. Ann Dermatol Venereol 2006;133:53-5.